Pacira BioSciences (PCRX) Net Margin (2010 - 2026)

Pacira BioSciences has reported Net Margin for 17 years, with the latest figure at 2.42% in Q2 2026.

• On a quarterly basis, Net Margin rose 509.0% year-over-year to 2.42% in Q2 2026; TTM through Jun 2026 was 1.96%, a 2002.0% increase from a year earlier, with the FY2025 full-year figure at 0.97%, up 1517.0% from the prior year.
• Net Margin was 2.42% for Q2 2026 at Pacira BioSciences, up from 1.64% in the prior quarter.
• The five-year high for Net Margin was 15.2% in Q2 2023, with the low at 85.11% in Q3 2024.
• Average Net Margin over 5 years is 1.07%, with a median of 2.94% recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Net Margin plunged 9173 bps in 2024, then soared 8813 bps in 2025.
• Over 5 years, Net Margin stood at 5.87% in 2022, then soared by 334 bps to 13.72% in 2023, then sank by 38 bps to 8.57% in 2024, then plunged by 90 bps to 0.83% in 2025, then surged by 191 bps to 2.42% in 2026.
• The last three Net Margin figures came in at 2.42% (Q2 2026), 1.64% (Q1 2026), and 0.83% (Q4 2025), per Business Quant data.